1. Home
  2. AERO vs PHVS Comparison

AERO vs PHVS Comparison

Compare AERO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AERO

Grupo Aeromexico S.A.B.

N/A

Current Price

$15.67

Market Cap

2.0B

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$27.88

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AERO
PHVS
Founded
1934
2015
Country
Mexico
Switzerland
Employees
4084
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AERO
PHVS
Price
$15.67
$27.88
Analyst Decision
Strong Buy
Buy
Analyst Count
7
10
Target Price
$28.57
$41.80
AVG Volume (30 Days)
643.8K
186.2K
Earning Date
04-10-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.01
N/A
Revenue Next Year
$4.10
N/A
P/E Ratio
$7.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.26
$11.51
52 Week High
$23.05
$29.85

Technical Indicators

Market Signals
Indicator
AERO
PHVS
Relative Strength Index (RSI) 55.59 54.53
Support Level $12.26 $24.55
Resistance Level $21.58 $28.06
Average True Range (ATR) 0.78 1.33
MACD 0.39 0.17
Stochastic Oscillator 92.57 60.61

Price Performance

Historical Comparison
AERO
PHVS

About AERO Grupo Aeromexico S.A.B.

Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: